- Cash and Cash Equivalents: $1.25 billion, significantly higher than the estimate of $941.4 million and up from $612.9 million year-over-year (y/y).
- Loss Per Share: $1.94, wider than last year’s $1.78 loss per share and falling short of the estimated $1.23 loss per share.
- R&D Expenses: $146.7 million, a 25% decrease y/y, but higher than the estimated $134.1 million.
- Net Product Revenues: $90.3 million, a 17% increase y/y and above the estimate of $87.9 million.
- SG&A Expenses: $106.6 million, a 26% increase y/y and above the estimated $95.8 million.
- 2024 Guidance: Company reiterates global ARIKAYCE revenue guidance in the range of $340 million to $360 million, reflecting double-digit growth compared to 2023.
- Analyst Ratings: 17 buys, 0 holds, 0 sells.
A look at Insmed Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
The long-term outlook for Insmed Inc, according to the Smartkarma Smart Scores, shows a promising future. With a strong emphasis on growth, resilience, and momentum, the company is positioned well for continued success. Insmed’s focus on developing innovative inhaled therapies for patients with orphan lung diseases indicates a commitment to addressing high unmet needs in the healthcare sector.
While the company may not currently score high on value or dividend factors, its robust growth, resilience, and momentum scores suggest a positive trajectory for Insmed Inc in the long run. Investors looking for a company with strong growth potential and a clear dedication to innovation may find Insmed Inc a compelling prospect for long-term investment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
